David R Gastfriend

Summary

Affiliation: Alkermes Inc
Country: USA

Publications

  1. ncbi request reprint Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence
    Onur Baser
    852 Winter St, Waltham, MA 02139 e mail
    Am J Manag Care 17:S222-34. 2011
  2. ncbi request reprint Cost and utilization outcomes of opioid-dependence treatments
    Onur Baser
    TATinMED Research and the University of Michigan, USA
    Am J Manag Care 17:S235-48. 2011
  3. ncbi request reprint Developing a baseline assessment battery: balancing patient time burden with essential clinical and research monitoring
    David R Gastfriend
    Addiction Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    J Stud Alcohol Suppl . 2005
  4. doi request reprint Intramuscular extended-release naltrexone: current evidence
    David R Gastfriend
    Alkermes, Inc, Waltham, Massachusetts 02451 1420, USA
    Ann N Y Acad Sci 1216:144-66. 2011
  5. ncbi request reprint Reduction in heavy drinking as a treatment outcome in alcohol dependence
    David R Gastfriend
    Alkermes, Cambridge, MA, USA
    J Subst Abuse Treat 33:71-80. 2007
  6. doi request reprint Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence
    Helen M Pettinati
    Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Alcohol Clin Exp Res 35:1804-11. 2011
  7. ncbi request reprint Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment
    STEPHANIE S O'MALLEY
    Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, New Haven, CT 06519, USA
    J Clin Psychopharmacol 27:507-12. 2007
  8. ncbi request reprint Early treatment response in alcohol dependence with extended-release naltrexone
    Domenic A Ciraulo
    Division of Psychiatry, Boston University School of Medicine, Boston, MA 02118 2393, USA
    J Clin Psychiatry 69:190-5. 2008
  9. pmc Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients
    Helen M Pettinati
    Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Alcohol Clin Exp Res 33:350-6. 2009
  10. pmc Effects of naltrexone treatment for alcohol-related disorders on healthcare costs in an insured population
    Henry R Kranzler
    Department of Psychiatry, University of Connecticut School of Medicine, Farmington, Connecticut 06030 2103, USA
    Alcohol Clin Exp Res 34:1090-7. 2010

Detail Information

Publications20

  1. ncbi request reprint Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence
    Onur Baser
    852 Winter St, Waltham, MA 02139 e mail
    Am J Manag Care 17:S222-34. 2011
    ..To determine the healthcare costs associated with treatment of alcohol dependence with medications versus no medication and across the 4 medications approved by the US Food and Drug Administration (FDA)...
  2. ncbi request reprint Cost and utilization outcomes of opioid-dependence treatments
    Onur Baser
    TATinMED Research and the University of Michigan, USA
    Am J Manag Care 17:S235-48. 2011
    ..To evaluate the healthcare costs associated with treatment of opioid-dependence disorder with medications versus no medication, and with the 4 agents approved by the US Food and Drug Administration (FDA)...
  3. ncbi request reprint Developing a baseline assessment battery: balancing patient time burden with essential clinical and research monitoring
    David R Gastfriend
    Addiction Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    J Stud Alcohol Suppl . 2005
    ..prior treatment history, motivation for change, self-efficacy, other psychiatric conditions, treatment expectations and network supports). Measures may be needed to interpret interactions that may be discovered between these modalities...
  4. doi request reprint Intramuscular extended-release naltrexone: current evidence
    David R Gastfriend
    Alkermes, Inc, Waltham, Massachusetts 02451 1420, USA
    Ann N Y Acad Sci 1216:144-66. 2011
    ..While more research is needed, current findings suggest that a formulation of naltrexone that was sought beginning over three decades ago is fulfilling its promise as an extended-release pharmacotherapeutic...
  5. ncbi request reprint Reduction in heavy drinking as a treatment outcome in alcohol dependence
    David R Gastfriend
    Alkermes, Cambridge, MA, USA
    J Subst Abuse Treat 33:71-80. 2007
    ....
  6. doi request reprint Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence
    Helen M Pettinati
    Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Alcohol Clin Exp Res 35:1804-11. 2011
    ....
  7. ncbi request reprint Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment
    STEPHANIE S O'MALLEY
    Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, New Haven, CT 06519, USA
    J Clin Psychopharmacol 27:507-12. 2007
    ..In conclusion, XR-NTX 380 mg prolonged abstinence and reduced the number of heavy drinking days and drinking days in patients who were abstinent for as few as 4 days before treatment initiation...
  8. ncbi request reprint Early treatment response in alcohol dependence with extended-release naltrexone
    Domenic A Ciraulo
    Division of Psychiatry, Boston University School of Medicine, Boston, MA 02118 2393, USA
    J Clin Psychiatry 69:190-5. 2008
    ..We sought to determine the time course for onset of effect of intramuscular injectable extended-release naltrexone (XR-NTX), which has demonstrated efficacy for alcohol dependence...
  9. pmc Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients
    Helen M Pettinati
    Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Alcohol Clin Exp Res 33:350-6. 2009
    ..2005). A 24-week, randomized, double-blind, placebo-controlled study established the efficacy and safety of XR-NTX in this patient population. In this report, the effect of XR-NTX on quality of life (QOL) was examined...
  10. pmc Effects of naltrexone treatment for alcohol-related disorders on healthcare costs in an insured population
    Henry R Kranzler
    Department of Psychiatry, University of Connecticut School of Medicine, Farmington, Connecticut 06030 2103, USA
    Alcohol Clin Exp Res 34:1090-7. 2010
    ..To determine the impact of treatment with oral naltrexone on healthcare costs in patients with alcohol-related disorders...
  11. pmc Persistence with oral naltrexone for alcohol treatment: implications for health-care utilization
    Henry R Kranzler
    Department of Psychiatry, University of Connecticut School of Medicine, Farmington, CT 06030 2103, USA
    Addiction 103:1801-8. 2008
    ..We examined prescriptions for oral naltrexone in a large, nationally distributed treatment population to identify characteristics and health-care utilization patterns associated with persistence...
  12. pmc Long-term opioid blockade and hedonic response: preliminary data from two open-label extension studies with extended-release naltrexone
    CHARLES P O'BRIEN
    Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Am J Addict 20:106-12. 2011
    ..The differential hedonic ratings suggest that, in patients who persist with long-term continuous therapy, XR-NTX may selectively inhibit the pleasure associated with drinking alcohol, compared to a variety of other activities. ..
  13. doi request reprint Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone
    Reginald L Dean
    Department of Life Sciences and Toxicology, Alkermes, Inc, 88 Sidney St, Cambridge, MA 02139, USA
    Pharmacol Biochem Behav 89:515-22. 2008
    ..Thus, opioid receptor blockade with XR-NTX can be overcome in rats with higher doses of opioids without further affecting respiration or locomotor activity...
  14. ncbi request reprint Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial
    James C Garbutt
    Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill 27599 7160, USA
    JAMA 293:1617-25. 2005
    ..However, adherence to daily oral pharmacotherapy can be problematic, and clinical acceptance and utility of oral naltrexone have been limited...
  15. pmc Advancing performance measures for use of medications in substance abuse treatment
    Cindy Parks Thomas
    Brandeis University, Institute for Behavioral Health, Heller School for Social Policy and Management, Waltham, MA 02454, USA
    J Subst Abuse Treat 40:35-43. 2011
    ..This article summarizes those findings by identifying a number of critical themes related to advancing SUD pharmacotherapy performance measures, highlighting examples from the field, and recommending actions for policy makers...
  16. ncbi request reprint Advances in the pharmacotherapy of alcoholism: challenging misconceptions
    Henry R Kranzler
    Department of Psychiatry, University of Connecticut Health Center, Farmington, Connecticut, USA
    Alcohol Clin Exp Res 30:272-81. 2006
    ..Gastfriend; (5) System Challenges in the Adoption of Pharmacotherapy, by Robert M. Swift; and (6) Pharmacotherapy for Alcohol Dependence: Strengths, Challenges, and Future Directions, by Mark L. Willenbring...
  17. pmc Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients
    Gary A Zarkin
    RTI International, 3040 Cornwallis Rd, Research Triangle Park, NC 27709, USA
    Arch Gen Psychiatry 65:1214-21. 2008
    ..The costs and cost-effectiveness of these combinations are unknown and of interest to clinicians and policy makers...
  18. ncbi request reprint Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial
    Raymond F Anton
    Center for Drug and Alcohol Programs, Medical University of South Carolina, Charleston 29425, USA
    JAMA 295:2003-17. 2006
    ..Alcohol dependence treatment may include medications, behavioral therapies, or both. It is unknown how combining these treatments may impact their effectiveness, especially in the context of primary care and other nonspecialty settings...
  19. ncbi request reprint The ASAM patient placement criteria: context, concepts and continuing development
    David R Gastfriend
    J Addict Dis 22:1-8. 2003
  20. ncbi request reprint Addiction denial and cognitive dysfunction: a preliminary investigation
    William Rinn
    Spaulding Rehabilitation Hospital, Boston, MA 02114, USA
    J Neuropsychiatry Clin Neurosci 14:52-7. 2002
    ..Cognitive deficiencies were identified through neuropsychological assessments. Persistent denial was significantly correlated with greater impairment of executive function, verbal memory, visual inference, and mental speed...